Wurz GT - Search Results

1

High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically.

Lara PN Jr, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J, Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. Lara PN Jr, et al. Among authors: wurz gt. Cancer Chemother Pharmacol. 1998;42(6):504-8. doi: 10.1007/s002800050852. Cancer Chemother Pharmacol. 1998. PMID: 9788578 Clinical Trial.

2

Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells.

Wiebe V, Koester S, Lindberg M, Emshoff V, Baker J, Wurz G, DeGregorio M. Wiebe V, et al. Invest New Drugs. 1992 Jul;10(2):63-71. doi: 10.1007/BF00873119. Invest New Drugs. 1992. PMID: 1386843

3

A bioassay for antiestrogenic activity--potential utility in drug development and monitoring effective in vivo dosing.

DeGregorio M, Wurz G, Emshoff V, Koester S, Minor P, Wiebe V. DeGregorio M, et al. Breast Cancer Res Treat. 1992;24(1):35-41. doi: 10.1007/BF01832356. Breast Cancer Res Treat. 1992. PMID: 1463870

4

Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells.

Baker WJ, Wiebe VJ, Koester SK, Emshoff VD, Maenpaa JU, Wurz GT, DeGregorio MW. Baker WJ, et al. Among authors: wurz gt. Breast Cancer Res Treat. 1992;24(1):43-9. doi: 10.1007/BF01832357. Breast Cancer Res Treat. 1992. PMID: 1463871

5

Flow cytometry: potential utility in monitoring drug effects in breast cancer.

Koester SK, Maenpaa JU, Wiebe VJ, Baker WJ, Wurz GT, Seymour RC, Koehler RE, DeGregorio MW. Koester SK, et al. Among authors: wurz gt. Breast Cancer Res Treat. 1994;32(1):57-65. doi: 10.1007/BF00666206. Breast Cancer Res Treat. 1994. PMID: 7819587 Review.

6

Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance.

Maenpaa J, Wiebe V, Wurz G, Koester S, Emshoff V, Seymour R, DeGregorio M. Maenpaa J, et al. Cancer Chemother Pharmacol. 1994;35(2):149-52. doi: 10.1007/BF00686638. Cancer Chemother Pharmacol. 1994. PMID: 7987992

7

Toremifene enhances cell cycle block and growth inhibition by vinblastine in multidrug resistant human breast cancer cells.

Baker WJ, Maenpaa JU, Wurz GT, Koester SK, Seymour RC, Emshoff VD, Wiebe VJ, DeGregorio MW. Baker WJ, et al. Among authors: wurz gt. Oncol Res. 1993;5(6-7):207-12. Oncol Res. 1993. PMID: 8123940

8

Topical toremifene: a new approach for cutaneous melanoma?

Maenpaa J, Dooley T, Wurz G, VandeBerg J, Robinson E, Emshoff V, Sipila P, Wiebe V, Day C, DeGregorio M. Maenpaa J, et al. Cancer Chemother Pharmacol. 1993;32(5):392-5. doi: 10.1007/BF00735925. Cancer Chemother Pharmacol. 1993. PMID: 8339391

9

Tamoxifen stimulates in vivo growth of drug-resistant estrogen receptor-negative breast cancer.

Maenpaa J, Wiebe V, Koester S, Wurz G, Emshoff V, Seymour R, Sipila P, DeGregorio M. Maenpaa J, et al. Cancer Chemother Pharmacol. 1993;32(5):396-8. doi: 10.1007/BF00735926. Cancer Chemother Pharmacol. 1993. PMID: 8339392

10

Targeting chemosensitizing doses of toremifene based on protein binding.

Wurz GT, Emshoff VD, DeGregorio MW, Wiebe VJ. Wurz GT, et al. Cancer Chemother Pharmacol. 1993;31(5):412-4. doi: 10.1007/BF00686157. Cancer Chemother Pharmacol. 1993. PMID: 8431976

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters